XP0 Stock Overview
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xenon Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.00 |
| 52 Week High | US$46.60 |
| 52 Week Low | US$26.20 |
| Beta | 1.18 |
| 1 Month Change | -1.02% |
| 3 Month Change | -3.94% |
| 1 Year Change | 13.37% |
| 3 Year Change | 160.00% |
| 5 Year Change | 369.99% |
| Change since IPO | 228.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| XP0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.0% | -4.3% | -2.5% |
| 1Y | 13.4% | -19.4% | -0.4% |
Return vs Industry: XP0 exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: XP0 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| XP0 volatility | |
|---|---|
| XP0 Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XP0 has not had significant price volatility in the past 3 months.
Volatility Over Time: XP0's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 255 | Ian Mortimer | www.xenon-pharma.com |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
Xenon Pharmaceuticals Inc. Fundamentals Summary
| XP0 fundamental statistics | |
|---|---|
| Market cap | €2.95b |
| Earnings (TTM) | -€171.36m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.2x
P/E RatioIs XP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XP0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$167.51m |
| Gross Profit | -US$167.51m |
| Other Expenses | US$14.88m |
| Earnings | -US$182.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XP0 perform over the long term?
See historical performance and comparison